- Details
- Piet Ost discusses the STORM trial, a randomized study comparing stereotactic body radiotherapy (SBRT) with elective nodal radiotherapy (ENRT) in oligometastatic prostate cancer patients. The trial, involving 80% PSMA-PET scanned patients, includes six months of androgen deprivation therapy in both arms. Results show significant benefits for ENRT in biochemical recurrence-free survival and locoreg...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a meta-analysis published in JAMA Oncology examining cardiovascular events associated with androgen receptor signaling inhibitors (ARSIs) in advanced prostate cancer. The study analyzes 24 randomized controlled trials across various prostate cancer stages, involving 22,166 patients. Results show a significant increase in both all-grade and grade 3+ cardiovas...
|
- Details
- Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 patients with up to three metastatic lesions, randomized into two arms. Results show improved biochemical and clinical progression-free survival in the combination arm. Dr. Marvaso highlights that pati...
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
- Details
- Oliver Sartor discusses radiopharmaceuticals with Germo Gericke. Dr. Gericke emphasizes the potential of targeted radioligand therapies, particularly for advanced cancers. He explores various isotopes, including Lutetium, Terbium, and Actinium, highlighting Actinium's promise in preclinical studies. Dr. Gericke discusses ideal target characteristics and Ariceum's innovative approach of targeting i...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zach Klaassen interviews Constantinos Zamboglou about a study on PSMA-PET/CT-guided salvage radiotherapy for recurrent prostate cancer after surgery. Dr. Zamboglou presents findings from a comparative analysis of PSMA-PET-guided and non-PSMA-guided salvage radiotherapy, using data from the SAKK09/10 trial and a retrospective database. The study demonstrates improved short- and mid-term biochemical...
|
- Details
- Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
|
- Details
- Oliver Sartor speaks with Michael Schultz about advances in radiopharmaceuticals for cancer treatment. Dr. Schultz discusses the advantages of using alpha-particle emitters, particularly lead-212, for targeted cancer therapy. He explains the rationale behind choosing lead-212, including its short half-life and the ability to use lead-203 for imaging. Dr. Schultz addresses distribution challenges a...
|